olanzaccord tablets 2.5 mg olanzapine 2.5 mg film-coated tablet blister pack
accord healthcare pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; microcrystalline cellulose; crospovidone; hypromellose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
olanzaccord tablets 7.5 mg olanzapine 7.5 mg film-coated tablets blister pack
accord healthcare pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate- dextroamphetamine saccha
bryant ranch prepack - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate 5 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful.
olmesartan medoxomil 40 mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - olmesartan medoxomil - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; olmesartan medoxomil
apo-olanzapine olanzapine 10 mg tablet blister pack
arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; hyprolose; microcrystalline cellulose - apo-olanzapine? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.
apo-olanzapine olanzapine 7.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - apo-olanzapine tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.
apo-olanzapine olanzapine 5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - apo-olanzapine tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate- dextroamphet
eon labs, inc. - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - mixed salts of a single entity amphetamine product are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least six of the foll
olmesar 20 (olmesartan medoxomil tablets 20mg)
camber laboratories sdn. bhd. - olmesartan medoxomil -
olmesar 40 (olmesartan medoxomil tablets 40mg)
camber laboratories sdn. bhd. - olmesartan medoxomil -